
MarkFariesMD
@markfariesmd
Surgical Oncologist
Melanoma Surgeon
Cancer Research
Immunotherapy
ID: 917139996120719360
http://www.theangelesclinic.org 08-10-2017 21:29:49
23 Tweet
363 Followers
200 Following


Congratulations to Robert Andtbacka for leading/presenting the neoadjuvant T-VEC study. cancernetwork.com/news/t-vec-immâŚ

Prof Omid Hamid MD the southern #California ROCKSTAR #Immunotherapist âYou always hurt the one you loveâ - need to optimize Ipi dose #Bridge18


Dr. Omid Hamid Omid Hamid MD is examining the IL-6 Receptor Inhibitor #Tocilizumab with #Ipilimumab & #Nivolumab to treat unresectable Stage 3 or 4 #Melanoma in a phase 2 study. @AngelesClinic #CedarsSinai #CedarsSinaiCancer #melanomaawarenessmonth cancertrialinfo.csmc.edu/adultcancersprâŚ

Wanted to notify all of Twitter that I am seeing patients @theangelesclinic direct 310-231-2164 - email [email protected] #melanoma #melasm #immunotherapy #SurgOnc #ImmunoOnc #immunooncology #PD1 #clinicaltrials


Nice work! Jason Luke, MD, FACP giving great talk on what's next in immunotherapy. #worldmelanomacongress




Prof Nicola Mozzillo melanoma surgeon extraordinaire receives award from Dr Paolo A. Ascierto for decades of leadership and advancing treatments to #FINISHCANCER / Dr Mozzilloâs address remembers Dr Don Morton @JohnWayneCI & @Prov_Health #Bridge2017 Fondazione Melanoma thanks MarkFariesMD


.Jeffrey Gershenwald MarkFariesMD & colleagues review the evidence-based changes in the AJCC 8th edition #Melanoma staging guidelines onlinelibrary.wiley.com/doi/10.3322/caâŚ
